IL6 and atherosclerosis: IL-6 has been shown to be positively linked with atherosclerosis and RCTs of treatments targeting the IL-6 pathway (e.g., ziltivekimab) in patients with high risk of atherosclerotic diseases demonstrated a reduction in CV event rates.30